Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 422 entries
Sorted by: Best Match Show Resources per page
Correction to "α7β2 Nicotinic Acetylcholine Receptors Assemble, Function, and Are Activated Primarily via Their α7-α7 Interfaces".

Molecular pharmacology

[No authors listed]
PMID: 27535999
Mol Pharmacol. 2016 Sep;90(3):410. doi: 10.1124/mol.111.074088err.

No abstract available.

Cite
Correction to "α7β2 Nicotinic Acetylcholine Receptors Assemble, Function, and Are Activated Primarily via Their α7-α7 Interfaces". Mol Pharmacol. 2016;90(3):410doi: 10.1124/mol.111.074088err.
(2016). Correction to "α7β2 Nicotinic Acetylcholine Receptors Assemble, Function, and Are Activated Primarily via Their α7-α7 Interfaces". Molecular pharmacology, 90(3), 410. https://doi.org/10.1124/mol.111.074088err
"Correction to "α7β2 Nicotinic Acetylcholine Receptors Assemble, Function, and Are Activated Primarily via Their α7-α7 Interfaces"." Molecular pharmacology vol. 90,3 (2016): 410. doi: https://doi.org/10.1124/mol.111.074088err
Correction to "α7β2 Nicotinic Acetylcholine Receptors Assemble, Function, and Are Activated Primarily via Their α7-α7 Interfaces". Mol Pharmacol. 2016 Sep;90(3):410. doi: 10.1124/mol.111.074088err. PMID: 27535999; PMCID: PMC4998669.
Copy Download .nbib Format: NLM
Correction to: "Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice".

Molecular pharmacology

[No authors listed]
PMID: 26349816
Mol Pharmacol. 2015 Oct;88(4):813. doi: 10.1124/mol.115.098376err.

No abstract available.

Cite
Correction to: "Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice". Mol Pharmacol. 2015;88(4):813doi: 10.1124/mol.115.098376err.
(2015). Correction to: "Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice". Molecular pharmacology, 88(4), 813. https://doi.org/10.1124/mol.115.098376err
"Correction to: "Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice"." Molecular pharmacology vol. 88,4 (2015): 813. doi: https://doi.org/10.1124/mol.115.098376err
Correction to: "Preclinical Evaluation of DMA, a Bisbenzimidazole, as Radioprotector: Toxicity, Pharmacokinetics, and Biodistribution Studies in Balb/c Mice". Mol Pharmacol. 2015 Oct;88(4):813. doi: 10.1124/mol.115.098376err. PMID: 26349816.
Copy Download .nbib Format: NLM
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine.

Molecular pharmacology

[No authors listed]
PMID: 17213995
Mol Pharmacol. 2007 Jan;71(1):388.

No abstract available.

Cite
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2007;71(1):388
(2007). Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. Molecular pharmacology, 71(1), 388.
"Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine." Molecular pharmacology vol. 71,1 (2007): 388.
Re: Henschler R, Brennscheidt U, Mertelsmann R, and Herrmann F (1991). Induction of c-jun expression in the myeloid leukemia cell line KG-1 by 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2007 Jan;71(1):388. PMID: 17213995.
Copy Download .nbib Format: NLM
Re: Yin MB, Li Z-R, Cao S, Durrani FA, Azrak RG, Frank C, and Rustum YM (2004) Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonin-68 and down-regulation of Cdc6 expression. Mol Pharmacol 66:153-160.

Molecular pharmacology

[No authors listed]
PMID: 16535772
Mol Pharmacol. 2006 Mar;69(3):1074.

No abstract available.

Cite
Re: Yin MB, Li Z-R, Cao S, Durrani FA, Azrak RG, Frank C, and Rustum YM (2004) Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonin-68 and down-regulation of Cdc6 expression. Mol Pharmacol 66:153-160. Mol Pharmacol. 2006;69(3):1074
(2006). Re: Yin MB, Li Z-R, Cao S, Durrani FA, Azrak RG, Frank C, and Rustum YM (2004) Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonin-68 and down-regulation of Cdc6 expression. Mol Pharmacol 66:153-160. Molecular pharmacology, 69(3), 1074.
"Re: Yin MB, Li Z-R, Cao S, Durrani FA, Azrak RG, Frank C, and Rustum YM (2004) Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonin-68 and down-regulation of Cdc6 expression. Mol Pharmacol 66:153-160." Molecular pharmacology vol. 69,3 (2006): 1074.
Re: Yin MB, Li Z-R, Cao S, Durrani FA, Azrak RG, Frank C, and Rustum YM (2004) Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonin-68 and down-regulation of Cdc6 expression. Mol Pharmacol 66:153-160. Mol Pharmacol. 2006 Mar;69(3):1074. PMID: 16535772.
Copy Download .nbib Format: NLM
Parkinson's Disease: A Role for the Immune System.

Current molecular pharmacology

German DC, Eagar T, Sonsalla PK.
PMID: 21675953
Curr Mol Pharmacol. 2011 Jun 15; Epub 2011 Jun 15.

Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with the loss of catecholaminergic neurons in several brain regions. The motor symptoms of the disease are related to degeneration of the midbrain dopaminergic neurons, which occurs some time after...

Cite
German DC, Eagar T, Sonsalla PK. Parkinson's Disease: A Role for the Immune System. Curr Mol Pharmacol. 2011;
German, D. C., Eagar, T., & Sonsalla, P. K. (2011). Parkinson's Disease: A Role for the Immune System. Current molecular pharmacology, .
German, Dwight C, et al. "Parkinson's Disease: A Role for the Immune System." Current molecular pharmacology vol. (2011).
German DC, Eagar T, Sonsalla PK. Parkinson's Disease: A Role for the Immune System. Curr Mol Pharmacol. 2011 Jun 15; Epub 2011 Jun 15. PMID: 21675953.
Copy Download .nbib Format: NLM
Correction to "CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells".

Molecular pharmacology

[No authors listed]
PMID: 30322842
Mol Pharmacol. 2018 Nov;94(5):1311. doi: 10.1124/mol.117.906err.

No abstract available.

Cite
Correction to "CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells". Mol Pharmacol. 2018;94(5):1311doi: 10.1124/mol.117.906err.
(2018). Correction to "CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells". Molecular pharmacology, 94(5), 1311. https://doi.org/10.1124/mol.117.906err
"Correction to "CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells"." Molecular pharmacology vol. 94,5 (2018): 1311. doi: https://doi.org/10.1124/mol.117.906err
Correction to "CCAAT/Enhancer-Binding Protein β (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells". Mol Pharmacol. 2018 Nov;94(5):1311. doi: 10.1124/mol.117.906err. PMID: 30322842.
Copy Download .nbib Format: NLM
Publishing in an ASPET Journal - What's in It for You?.

Molecular pharmacology

Vore M.
PMID: 29491043
Mol Pharmacol. 2018 Apr;93(4):286-287. doi: 10.1124/mol.117.112193.

No abstract available.

Cite
Vore M. Publishing in an ASPET Journal - What's in It for You?. Mol Pharmacol. 2018;93(4):286-287doi: 10.1124/mol.117.112193.
Vore, M. (2018). Publishing in an ASPET Journal - What's in It for You?. Molecular pharmacology, 93(4), 286-287. https://doi.org/10.1124/mol.117.112193
Vore, Mary. "Publishing in an ASPET Journal - What's in It for You?." Molecular pharmacology vol. 93,4 (2018): 286-287. doi: https://doi.org/10.1124/mol.117.112193
Vore M. Publishing in an ASPET Journal - What's in It for You?. Mol Pharmacol. 2018 Apr;93(4):286-287. doi: 10.1124/mol.117.112193. PMID: 29491043.
Copy Download .nbib Format: NLM
Correction to "Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis".

Molecular pharmacology

[No authors listed]
PMID: 29114082
Mol Pharmacol. 2017 Dec;92(6):627. doi: 10.1124/mol.116.105031err.

No abstract available.

Cite
Correction to "Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis". Mol Pharmacol. 2017;92(6):627doi: 10.1124/mol.116.105031err.
(2017). Correction to "Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis". Molecular pharmacology, 92(6), 627. https://doi.org/10.1124/mol.116.105031err
"Correction to "Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis"." Molecular pharmacology vol. 92,6 (2017): 627. doi: https://doi.org/10.1124/mol.116.105031err
Correction to "Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis". Mol Pharmacol. 2017 Dec;92(6):627. doi: 10.1124/mol.116.105031err. PMID: 29114082.
Copy Download .nbib Format: NLM
Correction to "Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore".

Molecular pharmacology

[No authors listed]
PMID: 26553115
Mol Pharmacol. 2015 Dec;88(6):1084. doi: 10.1124/mol.115.097550err.

No abstract available.

Cite
Correction to "Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore". Mol Pharmacol. 2015;88(6):1084doi: 10.1124/mol.115.097550err.
(2015). Correction to "Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore". Molecular pharmacology, 88(6), 1084. https://doi.org/10.1124/mol.115.097550err
"Correction to "Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore"." Molecular pharmacology vol. 88,6 (2015): 1084. doi: https://doi.org/10.1124/mol.115.097550err
Correction to "Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore". Mol Pharmacol. 2015 Dec;88(6):1084. doi: 10.1124/mol.115.097550err. PMID: 26553115; PMCID: PMC4658598.
Copy Download .nbib Format: NLM
Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats.

Current molecular pharmacology

Samini M, Farkhondeh T, Azimi-Nezhad M, Samarghandian S.
PMID: 32718302
Curr Mol Pharmacol. 2021 Oct 25;14(4):597-603. doi: 10.2174/1874467213666200727123224.

BACKGROUND: Buprenorphine (BUP), a "synthetic derivative of the opioid alkaloid thebaine", may be associated with cellular damage in the central nervous system.AIMS: This study was designed to investigate the effects of low and high doses of BUP on oxidative...

Cite
Samini M, Farkhondeh T, Azimi-Nezhad M, et al. Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats. Curr Mol Pharmacol. 2021;14(4):597-603doi: 10.2174/1874467213666200727123224.
Samini, M., Farkhondeh, T., Azimi-Nezhad, M., & Samarghandian, S. (2021). Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats. Current molecular pharmacology, 14(4), 597-603. https://doi.org/10.2174/1874467213666200727123224
Samini, Mohammad, et al. "Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats." Current molecular pharmacology vol. 14,4 (2021): 597-603. doi: https://doi.org/10.2174/1874467213666200727123224
Samini M, Farkhondeh T, Azimi-Nezhad M, Samarghandian S. Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats. Curr Mol Pharmacol. 2021 Oct 25;14(4):597-603. doi: 10.2174/1874467213666200727123224. PMID: 32718302.
Copy Download .nbib Format: NLM
Correction to "MicroRNA hsa-miR-1301-3p Regulates Human ADH6, ALDH5A1 and ALDH8A1 in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway".

Molecular pharmacology

[No authors listed]
PMID: 32718916
Mol Pharmacol. 2020 Aug;98(2):181. doi: 10.1124/molpharm.120.000109.

No abstract available.

Cite
Correction to "MicroRNA hsa-miR-1301-3p Regulates Human ADH6, ALDH5A1 and ALDH8A1 in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway". Mol Pharmacol. 2020;98(2):181doi: 10.1124/molpharm.120.000109.
(2020). Correction to "MicroRNA hsa-miR-1301-3p Regulates Human ADH6, ALDH5A1 and ALDH8A1 in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway". Molecular pharmacology, 98(2), 181. https://doi.org/10.1124/molpharm.120.000109
"Correction to "MicroRNA hsa-miR-1301-3p Regulates Human ADH6, ALDH5A1 and ALDH8A1 in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway"." Molecular pharmacology vol. 98,2 (2020): 181. doi: https://doi.org/10.1124/molpharm.120.000109
Correction to "MicroRNA hsa-miR-1301-3p Regulates Human ADH6, ALDH5A1 and ALDH8A1 in the Ethanol-Acetaldehyde-Acetate Metabolic Pathway". Mol Pharmacol. 2020 Aug;98(2):181. doi: 10.1124/molpharm.120.000109. PMID: 32718916.
Copy Download .nbib Format: NLM
Correction to "Agonist-Dependent and-Independent .

Molecular pharmacology

[No authors listed]
PMID: 29945897
Mol Pharmacol. 2018 Aug;94(2):895. doi: 10.1124/mol.117.108555err.

No abstract available.

Cite
Correction to "Agonist-Dependent and-Independent . Mol Pharmacol. 2018;94(2):895doi: 10.1124/mol.117.108555err.
(2018). Correction to "Agonist-Dependent and-Independent . Molecular pharmacology, 94(2), 895. https://doi.org/10.1124/mol.117.108555err
"Correction to "Agonist-Dependent and-Independent ." Molecular pharmacology vol. 94,2 (2018): 895. doi: https://doi.org/10.1124/mol.117.108555err
Correction to "Agonist-Dependent and-Independent . Mol Pharmacol. 2018 Aug;94(2):895. doi: 10.1124/mol.117.108555err. PMID: 29945897; PMCID: PMC6027136.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 422 entries